Treatment News : Hep C, HIV Drug-Drug Interaction Studies Must Be a Priority, Activists Say

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » February 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

February 16, 2012

Hep C, HIV Drug-Drug Interaction Studies Must Be a Priority, Activists Say

An international Hep C activist group is calling on government regulators and pharmaceutical companies developing therapies for hepatitis C virus (HCV) infection to conduct necessary interaction studies involving other medications commonly used by people living with HCV and HIV/HCV coinfection as early as possible. 

The Hepatitis C Community Advisory Board (HCAB), in a statement released Thursday, February 16, stressed their belief that it is possible to conduct such drug-drug interaction studies prior to U.S. Food and Drug Administration (FDA) approval without delaying development of novel therapies for HCV.

Because many emerging HCV drugs, frequently referred to as direct-acting antivirals (DAAs), are broken down (metabolized) by the same enzyme pathways responsible for processing many other medications used by people living with hepatitis C, including those who are also HIV positive, thoroughly exploring potential drug-drug interactions and ways to circumvent problems is important. Left unchecked, interactions can significantly decrease the effectiveness of some drugs while potentially increasing the risk of serious side effects from other drugs.

Early knowledge of interactions between DAAs and HIV-treating antiretrovirals is particularly crucial, given that roughly one third of people living with HIV are coinfected with HCV and are becoming increasingly dependent on the rapid availability of new DAAs.

“In recognition of the suboptimal efficacy and tolerability of peginterferon and ribavirin, rapid trajectory of liver disease progression and increasing mortality from HCV-related complications among HIV/HCV coinfected patients,” the HCAB statement reads, “regulators in the [United States] and the [European Union should] encourage sponsors to conduct trials in HIV/HCV coinfected patients prior to approval for [people living with HCV but not HIV].”

The HCAB statement stems from concerns related to the recent discovery of drug-drug interactions between Merck’s Victrelis (boceprevir) and Norvir (ritonavir)-boosted protease inhibitors used to treat HIV infection. “Although we commend [Merck] for opening one of the first coinfection trials with a DAA, we were outraged that Merck chose not to conduct [drug-drug interaction studies] with commonly used antiretroviral agents prior to launching the trial, and prior to gaining approval for boceprevir.”

“Vertex and Tibotec,” the statement authors add, “were able to bring [Incivek] telaprevir to market with a much fuller portfolio of [drug-drug interaction] data, although both drugs were developed within the same timeframe.”

HCAB is asking FDA, the European Medicines Agency (EMA) and pharmaceutical companies to work together to minimize potential harm to people living with HCV, including people coinfected with HIV and HCV, from uncharacterized drug-drug interactions.

“Furthermore,” the statement concludes, “we call upon sponsors to perform [drug-drug interaction] studies (as indicated by metabolic profile of their drug or drugs) with [Department of Health and Human Services, European AIDS Clinical Society and World Health Organization]-recommended antiretroviral agents for first-line, and treatment-experienced HIV/HCV coinfected people prior to approval, and strongly encourage studies of hormonal contraceptives, methadone, buprenorphine, lipid lowering agents, immunosuppressive drugs, herbal remedies, and commonly prescribed psychiatric medications.”

Search: hepatitis C, HCAB, HCV, HIV, drug-drug interactions, DDIs, metabolism, direct-acting antivirals, DAAs, protease inhibitors, Victrelis, boceprevir, Merck, FDA, EMA, DHHS, pharmaceutical companies


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adoniz89
    san dimas
    California


    soy_Ric
    Rochester
    New York


    usuallyhappy
    Palm Springs
    California


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.